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Despite ongoing research efforts, drug addiction continues to pose a largely unmet medical need and is
fueled by high rates of recidivism. The need for more effective interventions aimed at relapse
prevention has led many researchers to re-evaluate current strategies and explore new and revisit old
approaches to the problem. In their paper in the current issue of “Neuropsychopharmacology”,
Heinsbroek, Furbish and Peters use a rat model to explore the potential utility of an aversive
“counterconditioning” approach, in which aversive stimuli are paired with drug associated
cues/context with the goal of dampening their ability to elicit drug-seeking behavior. Using aversive
conditioning to modify behavior is among the earliest ideas of psychology, dating back to the early
20th century when John B. Watson and Rosalie Rayner demonstrated that such an approach could be
used to establish fear reactions to a previously rewarding stimulus (a lab rat) in a 9-month-old child.

In their paper, Heinsbroek and colleagues test the ability of the kappa opioid receptor (KOR) agonist,
U50,488 (U50), a compound with established aversive properties, to counter-condition cocaineassociated cues, thereby attenuating their ability to evoke cocaine-seeking behavior. In the study, rats
underwent repeated cocaine self-administration, followed by a 7-day abstinence period, after which
they received a single dose of the KOR agonist or vehicle prior to re-introduction into the drug
environment under extinction conditions in which responding no longer resulted in cocaine delivery. In
addition to reducing responding during the initial retrieval session, the single U50 treatment
significantly attenuated later reinstatement of cocaine seeking upon response-contingent cue
presentation. This effect was dependent on KOR-induced activation of p38 MAP kinase signaling. The
authors interpret their findings as reflecting KOR-mediated counterconditioning such that the new
association between the aversive effects of the KOR agonist and the unrewarded operant response
within the drug context counteracts the previously established cocaine association. They conclude
that, to the extent that drug-associated stimuli can be isolated and introduced into a laboratory
setting, KOR agonist delivery may be used to establish new aversive associations that reduce the
likelihood of future drug-seeking behavior and relapse. Overall, the authors’ findings are consistent
with previous work demonstrating that KOR agonists can counteract the rewarding effects of cocaine
itself (see e.g., refs. [1] and [2]).
The concept of using aversive conditioning to curb drug use is not a new one. Indeed, studies dating
back to the 1970’s have attempted to establish associations between aversive and drug-related stimuli
during therapy with the objective of reducing recidivism with limited success (see e.g., ref. [3]).
However, several interesting observations by Heinsbroek and colleagues may better define how
aversive stimuli or, more specifically, signaling processes engaged by aversive stimuli, may be better
leveraged to reduce relapse risk.
The first observation is that the ability of KOR agonist administration prior to the retrieval session to
“counter-condition” cue-induced cocaine seeking was not reproduced by lithium chloride (LiCl)
administration at a dose that produces place aversion, reward devaluation, and gastric malaise. This
finding was somewhat surprising, considering that KORs have been reported to mediate the aversive
effects of stressors (see e.g., ref. [4]), although KOR mediation of LiCl effects has not been
demonstrated. However, the finding is consistent with a previous report that the ability of footshock to
“counter-condition” drug-cue associations resulting from cocaine self-administration is transient at
best (see e.g., [5]). It may be that parallel processes engaged by LiCl and other stressors can offset or
interfere with the effects of KOR activation that attenuate later drug seeking. Thus, the authors’
findings suggest that specifically targeting the KOR and its downstream signaling mechanisms (e.g.,
p38/MAPK) can provide a pharmacological means for isolating components of the aversive response
that can counteract or disrupt drug associations and attenuate later relapse susceptibility.

The second observation may provide insight regarding the precise KOR-regulated component of the
aversive response that underlies the observed effect on cocaine seeking. The authors found that the
ability of U50 to reduce later drug seeking was dependent not only on administration of U50 but also
access to the previously active lever in the context suggesting a new or modified association is
occurring that influences subsequent behavior. KORs are broadly distributed in areas of the brain that
regulate associative learning, including the NAc and VTA. In fact, VTA KOR activation is required for
both kappa agonist-induced reductions in NAc dopamine concentration and aversion learning [6]. The
ability of KOR-induced signaling to inhibit dopamine neurons in the VTA [7] or alter downstream
dopamine signaling via effects on NAc MSNs [8] could be particularly relevant to the authors’
observations. It has long been proposed that a key function of dopamine is to encode error in reward
prediction [9]. Elevated dopaminergic signaling in response to drug-predictive cues incentivize behavior
while pauses in dopamine release are associated with reward omission and may reduce the likelihood
of subsequent responding. In the latter case, an intriguing potential explanation for the observed
response-dependent effects of U50 is that KOR activation produces a pharmacological enhancement of
negative prediction error via suppressed dopaminergic signaling. Notably, suppression of dopamine
signaling by KOR activation could also account for the acute attenuation of drug seeking by U50 during
the initial retrieval session, as signaling in the nucleus accumbens has been implicated in the
incentivizing properties of predictive cues. While appealing, this possible explanation has its
limitations. First, LiCl, which does not produce the same effects on later cue-induced cocaine seeking,
has also been demonstrated to attenuate dopamine signaling [10]. However, the mechanism, duration,
and intensity of LiCl action is vastly different than U50 and all of these factors are relevant for proper
associative learning. Second, although p38 has been implicated in many KOR effects, it may not be
required for the ability of KOR agonists to attenuate dopamine release, at least not stimulated
dopamine release as measured using in vivo cyclic voltammetry in mice with a constitutive loss of p38
in midbrain dopamine neurons [7]. It is likely that both KOR-mediated reductions in dopamine signaling
and KOR-mediated p38 activation are required for proper aversion learning. This raises the intriguing
possibility that these distinguishable KOR-mediated signals may each contribute to different aspects of
an animal’s ability to learn about an aversive outcome. If this is the case, then discerning their
respective contributions to this process could lead to the development of better therapeutics with
fewer off-target dysphoric effects. Despite these limitations, the possibility that KOR regulation of
dopaminergic signaling via actions in the VTA and/or nucleus accumbens contributes to the observed
effects merits further investigation. Although the authors did not conduct brain region-specific
manipulations in their paper, their findings establish an important starting point for a more targeted
investigation of the precise mechanisms through which KOR agonists diminish the ability of drugassociated cues to elicit drug seeking.

Although the findings in the paper are important, there are a number of practical considerations that
may limit immediate clinical application. First, ideal interventions involving counterconditioning
approaches will require the identification and isolation of relevant drug-associated cues and their
recapitulation in a therapy environment in a way that incorporates the operational act of drug seeking.
While challenging, it is possible that such obstacles could be overcome through the use of guided
imagery, possibly facilitated by modern technology such as virtual reality platforms. A bigger problem
may be the limited efficacy of the approach. Extinction-based approaches that successfully mitigate
drug-seeking behaviors often are limited to the extinction-context, thus latent or suppressed drug
seeking behavior remains susceptible to renewal/relapse. Therefore, a demonstration that the kappamediated enhancement of operant extinction, when acquired outside of the drug context, carries over
to reduced drug seeking within the original drug context would increase enthusiasm for kappa
mediated counterconditioning approaches. Furthermore, although U50 administration significantly
attenuated cue-induced drug seeking, blockade of reinstatement was incomplete. In human
populations, where such levels of drug-seeking behavior will likely translate to use and, as a result,
drug-cue associations will be re-established. Finally, the undesirable effects of KOR agonist drugs in
human populations, which includes intense dysphoria and psychotomimetic effects has been welldocumented and could limit clinical utility. However, as newer medications targeting KORs (e.g., biased
agonists) and downstream signaling mechanisms are developed, the feasibility of using them
therapeutically should increase.
In conclusion, while more work is needed to understand the underlying mechanism, the paper by
Heinsbroek and colleagues raises the intriguing possibility that, to the extent that aversion-based
approaches used in conjunction with extinction-based therapy represent a viable option for treating
drug addiction, KOR agonist medications may provide an opportunity for more precise targeting of
aversion-related processes that reduce the likelihood that drug-associated cues will serve as relapse
triggers.
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